S&P/ASX All Ordinaries (ASX: XAO) shares are up 0.58% to 8,606.1 points at the time of writing on Thursday.
Meantime, Tamim Asset Management has issued a note on three ASX All Ords shares to buy.
The broker says these stocks offer ASX investors an opportunity to capitalise on sector trends as well as company-specific growth drivers.
In an article, Tamim says these three companies share common themes of "resilience and the potential for strong future performance".
Let's check them out.
3 ASX All Ords shares primed for growth
Humm Group (ASX: HUM)
The Humm share price is 82 cents on Thursday, down 1.20% for the day and up 82% over the past 12 months.
Tamim said Humm had a difficult year but was showing signs of recovery.
The broker said the financial services company had positioned itself for future growth through cost-cutting measures and expansion of its commercial portfolio.
Tamim noted that Humm reported a normalised annual cash profit of $60.6 million, reflecting a 19% decrease from the prior year. This was largely due to the impact of rising interest rates, economic uncertainty and increased competition in the buy now, pay later sector.
Humm is expanding its commercial portfolio, which Tamim says has strong growth potential:
Humm could present an intriguing opportunity for investors who are willing to look beyond its recent challenges and focus on its long-term growth potential.
Praemium Ltd (ASX: PPS)
The Praemium share price is currently trading at 56.5 cents, down 1.74% today and up almost 1% over the past 12 months.
Tamim says Praemium's scalable business model, strong revenue growth, and product innovation make it a compelling investment opportunity in the technology arena.
The broker said Praemium delivered solid financial results for the year, with EBITDA of $21.5 million. This was driven by a particularly strong second-half performance. Tamim commented:
This growth was underpinned by Praemium's investment in capability, resilience, and IT security during the first half, which laid the groundwork for its subsequent financial success.
Tamim regards Praemium's acquisition of the OneView business from Iress Ltd (ASX: IRE) as a great strategic decision. The broker says it has enhanced the company's revenue, as well as its market profile.
The asset manager commented:
Looking ahead, Praemium's growth prospects appear strong. The company has identified a gap in the market for next-generation IDPs (Investment Data Platforms), which it is poised to address with its new offerings. This product innovation is expected to drive further revenue growth and expand Praemium's customer base to address the non custodial market for high net worth investors.
Australian Clinical Labs Ltd (ASX: ACL)
This ASX All Ords health care share is trading at $3.69, down 0.27% on Thursday and up 34% over the past 12 months.
Tamim noted a solid start to FY25 for Australian Clinical Labs, including improving margins.
It says the ASX All Ords share is undervalued and an attractive opportunity in the health care sector.
The broker noted the pathology provider's solid financial results despite a significant decline in COVID-related revenue. Underlying EBIT came in at $62.6 million, in line with the company's FY24 guidance.
The second half of the year was especially strong, with underlying EBIT growing to $39.1 million, representing an 11% margin.
The company's ability to drive margin expansion in the second half of the year reflects the success of its cost control measures and its focus on operational efficiency.
ACL has carried this positive momentum into FY25, with strong growth already evident in the early months of the fiscal year.
Tamim said Australian Clinical Labs had a strong balance sheet, and the ASX All Ords share's dividend yield remained attractive.
Looking ahead, ACL appears poised for a re-rating, particularly if it continues to deliver strong financial results in FY25 where we estimate it is highly likely to upgrade guidance at the AGM or first half result.
